CD8A and neoplasm: The central principle is to enhance the anti-tumor activity of CD8 + cytotoxic T lymphocytes (CTLs), either by stimulating their activation against tumor-associated antigens (TAAs) or by blocking the immune-suppressing signals that decrease the number and exhaust the cytotoxic function of CTLs.